

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
13 March 2003 (13.03.2003)

PCT

(10) International Publication Number
WO 03/020299 A1

(51) International Patent Classification⁷: **A61K 38/00**

(21) International Application Number: PCT/US02/27855

(22) International Filing Date: 29 August 2002 (29.08.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
09/945,517 30 August 2001 (30.08.2001) US

(63) Related by continuation (CON) or continuation-in-part (CIP) to earlier application:
US 09/945,517 (CIP)
Filed on 30 August 2001 (30.08.2001)

(71) Applicant (for all designated States except US): **KIRIN-AMGEN, INC.** [US/US]; 1209 Orange Street, Wilmington, DE 19801 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **LI, Tiansheng**

[US/US]; 160 Via Fiesta Street, Newbury Park, CA 91320 (US). **CHANG, Byeong, S.** [KR/US]; 1619 Fox Springs Circle, Thousand Oaks, CA 91320 (US). **SLOEY, Christopher** [US/US]; 5421 Kester Avenue #215, Sherman Oaks, CA 91411 (US).


(74) Agents: **ODRE, Steven, M.** et al.; Amgen Inc., One Amgen Center Drive, M/S 27-4-A, Thousand Oaks, CA 91320-1799 (US).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK,

[Continued on next page]

(54) Title: L-METHIONINE AS A STABILIZER FOR NESP/EPO IN HSA-FREE FORMULATIONS



(57) Abstract: The present invention relates to single use and multi-dose pharmaceutical formulations comprising a biologically active agent and methionine, wherein said formulations demonstrate improved stability, and wherein said formulations do not contain human serum albumin.

BEST AVAILABLE COPY

WO 03/020299 A1



TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

Published:

- *with international search report*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*

L-METHIONINE AS A STABILIZER FOR NESP/EPO IN HSA-FREE
FORMULATIONS

BACKGROUND OF THE INVENTION

5

Due to recent advances in genetic and cell engineering technologies, proteins known to exhibit various pharmacological actions in vivo are capable of being produced in large amounts for pharmaceutical applications. Such proteins include erythropoietin (EPO), granulocyte colony-stimulating factor (G-CSF), interferons (alpha, beta, gamma, consensus), tumor necrosis factor binding proteins (TNFbp), interleukin-1 receptor antagonist (IL-1ra), brain-derived neurotrophic factor (BDNF), keratinocyte growth factor (KGF), stem cell factor (SCF), megakaryocyte growth differentiation factor (MGDF), osteoprotegerin (OPG), glial cell line derived neurotrophic factor (GDNF), obesity protein (OB protein), and novel erythropoiesis stimulating protein (NESP).

EPO is a glycoprotein hormone necessary for the maturation of erythroid progenitor cells into erythrocytes. It is produced in the kidney and is essential in regulating levels of red blood cells in the circulation. Conditions marked by low levels of tissue oxygen signal increased production of EPO, which in turn stimulates erythropoiesis. A loss of kidney function as is seen in chronic renal failure (CRF), for example, typically results in decreased production of EPO and a concomitant reduction in red blood cells. Human urinary EPO was purified by Miyake et al., *J. Biol. Chem.*, 252:5558 (1977) from patients with aplastic anemia. However, the amount of purified EPO protein obtained from this source was insufficient for therapeutic applications. The identification and

cloning of the gene encoding human EPO and expression of recombinant protein was disclosed in U.S. Patent No. 4,703,008 to Lin, the disclosure of which is incorporated herein by reference. A method for
5 purification of recombinant human erythropoietin from cell medium is disclosed in U.S. Patent No. 4,667,016 to Lai et. al., which is incorporated herein by reference. The production of biologically active EPO from mammalian host cells has made available, for the
10 first time, quantities of EPO suitable for therapeutic applications. In addition, knowledge of the gene sequence and the increased availability of purified protein has led to a better understanding of the mode of action of this protein.

15 Both human urinary derived EPO (Miyake et al. *supra*) and recombinant human EPO expressed in mammalian cells contain three N-linked and one O-linked oligosaccharide chains which together comprise about 40% of the total molecular weight of the glycoprotein.
20 N-linked glycosylation occurs at asparagine residues located at positions 24, 38 and 83 while O-linked glycosylation occurs at a serine residue located at position 126 (see Lai et al., *J. Biol. Chem.*, 261:3116 (1986); Broudy et al., *Arch. Biochem. Biophys.*, 265:329
25 (1988)). The oligosaccharide chains have been shown to be modified with terminal sialic acid residues with N-linked chains typically having up to four sialic acids per chain and O-linked chains having up to two sialic acids. An EPO polypeptide may therefore
30 accommodate up to a total of 14 sialic acids.

Various studies have shown that alterations of EPO carbohydrate chains can affect biological activity. In one study, however, the removal of N-linked or O-linked oligosaccharide chains singly or
35 together by mutagenesis of asparagine or serine

residues that are glycosylation sites sharply reduces *in vitro* activity of the altered EPO that is produced in mammalian cells; Dube et. al., *J. Biol. Chem.*, 263:17516 (1988). However, DeLorme et al., *Biochemistry*, 31:9871-9876 (1992) reported that removal of N-linked glycosylation sites in EPO reduced *in vivo* but not *in vitro* biological activity.

The relationship between the sialic acid content of EPO and *in vivo* biological activity was disclosed by determining the *in vivo* activity of isolated EPO isoforms. It was found that a stepwise increase in sialic acid content per EPO molecule gave a corresponding stepwise increase in *in vivo* biological activity as measured by the ability of equimolar concentrations of isolated EPO isoforms to raise the hematocrit of normal mice; Egrie et al., *Glycoconjugate J.*, 10:263 (1993). Those EPO isoforms having higher sialic acid content also exhibited a longer serum half-life but decreased affinity for the EPO receptor, suggesting that serum half-life is an important determinant of *in vivo* biological activity.

In the U.S., EPO has been used in the treatment of chronic renal failure maintained on dialysis as well as pre-dialysis, and in the treatment of anemia secondary to chemotherapy treatment in cancer and in anemia associated with zidovudine treatment of HIV infection. Worldwide, EPO has been used to treat anemia associated with prematurity, sickle cell anemia, rheumatoid arthritis, and bone marrow transplantation; Markham et al., *Drugs*, 49:232-254 (1995).

NESP is a hyperglycosylated erythropoietin analog having five changes in the amino acid sequence of rHuEPO which provide for two additional carbohydrate chains. More specifically, NESP contains two additional N-linked carbohydrate chains at amino acid

residues 30 and 88 (numbering corresponding to the sequence of human EPO) (see PCT Application No. US94/02957, herein incorporated by reference in its entirety). NESP is biochemically distinct from EPO, 5 having a longer serum half-life and higher *in vivo* biological activity; Egrie et al., *ASH 97, Blood*, 90:56a (1997). NESP has been shown to have ~3 fold increase in serum half-life in mice, rats, dogs and man; Id. In mice, the longer serum half-life and 10 higher *in vivo* activity allow for less frequent dosing (once weekly or once every other week) compared to rHuEPO to obtain the same biological response; Id.

A pharmacokinetic study demonstrated that, consistent with the animal studies, NESP has a 15 significantly longer serum half-life than rHuEPO in chronic renal failure patients, suggesting that a less frequent dosing schedule may also be employed in humans; MacDougall, et al., *J American Society of Nephrology*, 8:268A (1997). A less frequent dosing 20 schedule would be more convenient to both physicians and patients, and would be particularly helpful to those patients involved in self-administration. Other advantages to less frequent dosing may include less drug being introduced into patients, a reduction in the 25 nature or severity of the few side-effects seen with rHuEPO administration, and increased compliance.

Although commercially available EPO and NESP formulations are generally well tolerated and stable, consideration should be given to the fact that, under 30 extreme conditions, such proteins may be unstable and undergo various undesirable physiochemical degradations during manufacturing, handling, and storage conditions. Such degradations include aggregation, inactivation, and oxidation of methionine residues, and such 35 degradations may be accelerated by external factors

such as heat and light, or in formulations that are free of human blood products such as albumin, or in multi-dose formulations which contain preservatives such as benzyl alcohol.

5 Methods of inhibiting oxidation in methionine-containing polypeptides have been described; Takruri et al., U.S. Patent No. 5,272,135 (December 21, 1993). Specifically, Takruri describes methods of inhibiting the oxidation of methionine residue(s) in
10 liquid or semi-liquid preparations, said preparations comprising polypeptides having amino acid sequences comprising at least one methionine residue. The prevention of methionine oxidation is said to be accomplished by the addition of free L-methionine to
15 the preparations in an amount sufficient to inhibit oxidation of the methionine residue(s) in the polypeptide. The oxidation of the methionine residues is said to be associated with the plastic containers, e.g., polypropylene or low density polyethylene (LDPE),
20 which are readily permeable to oxygen, and within which the preparations are stored. The polypeptides contemplated for use in Takruri are growth factors, and the preparations tested are ophthalmic aqueous-based preparations of epidermal growth factor (EGF).
25 Preparations containing EPO or NESP, or any other glycosylated protein are not discussed, nor are formulations which are HSA-free, multi-dose, or HSA-free multi-dose discussed.

30 SUMMARY OF THE INVENTION

 The present invention provides pharmaceutical formulations of EPO and/or NESP wherein the incorporation of methionine and other stabilizing
35 agents into said formulations provide for a more stable

formulation, even in extreme conditions wherein critical degradations induced by light, heat, impurities in additives, leacheates in the prefilled syringes, the manufacturing process, storage,
5 transportation, and handling may otherwise occur.

Importantly, the formulations also demonstrate improved stability in HSA-free formulations and HSA-free multi-dose formulations containing preservatives, wherein the critical degradations may be
10 more pronounced.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 is a graph depicting the effect of
15 free methionine on the aggregation of NESP during exposure to light. NESP in phosphate buffered saline was exposed to ultraviolet light for 4 hours at room temperature.

20 Figure 2 is a graph depicting the effect of free methionine on the aggregation of NESP in the presence of 1% benzyl alcohol during storage at 2-8°C. Samples containing 500 µg/mL of NESP were stored for 13 months.

25 Figure 3 is a graph depicting the effect of various additives and treatment on the oxidation of methionine 54 residue in NESP during incubation for 90 days at 37°C. % oxidation was determined by tryptic
30 mapping followed by Reversed-phase HPLC and mass spectrometry.

Figure 4 is a graph depicting the effect of free methionine on the oxidation of NESP in a preserved

formulation containing 1% benzyl alcohol. 0-20mM free methionine was tested and samples were incubated at 4°C for 56 days.

5 Figure 5 is a graph depicting the effect of free methionine on the oxidation of NESP in a preserved formulation containing 1% benzyl alcohol. 0-20mM free methionine was tested and samples were incubated at 29°C for 56 days.

10 Figure 6 compares the tryptic maps of EPO in solutions at pH 7.0 \pm benzyl alcohol and \pm free L-methionine.

15 Figure 7 is a graph comparing NESP methionine oxidation rates with and without purging (10 minutes) with nitrogen. % methionine oxidation is plotted versus benzaldehyde concentration. 0.1 mg/ml NESP was tested.

20 Figure 8 compares the tryptic maps of over-oxidized NESP samples. Met-54 was fully oxidized for all samples shown in the figure. Numbers depicted on the figure represent the concentration of methionine
25 added to the samples.

DETAILED DESCRIPTION OF THE INVENTION

 "Excipient" is defined herein as a non-
30 therapeutic agent added to a pharmaceutical composition to provide a desired effect, e.g. stabilization, isotonicity.

 "Polypeptide" is defined herein as natural, synthetic, and recombinant proteins or peptides having

more than about 10 amino acids, and having a desired biological activity.

As used herein, biologically active agents refers to recombinant or naturally occurring polypeptides, whether human or animal, useful for prophylactic, therapeutic or diagnostic application. The biologically active agent can be natural, synthetic, semi-synthetic or derivatives thereof. Contemplated active agents include peptides, small molecules, carbohydrates, nucleic acids, lipids, proteins, and analogs thereof. One skilled in the art will readily be able to adapt a desired biologically active agent to the compositions of present invention.

Proteins contemplated for use would include but are not limited to interferon consensus (see, U.S. Patent Nos. 5,372,808, 5,541,293 4,897,471, and 4,695,623 hereby incorporated by reference including drawings), granulocyte-colony stimulating factors (see, U.S. Patent Nos. 4,810,643, 4,999,291, 5,581,476, 5,582,823, and PCT Publication No. 94/17185, hereby incorporated by reference including drawings), interleukins (see, U.S. Patent No. 5,075,222, hereby incorporated by reference including drawings), erythropoietins (see, U.S. Patent Nos. 4,703,008, 5,441,868, 5,618,698 5,547,933, and 5,621,080 hereby incorporated by reference including drawings), stem cell factor (PCT Publication Nos. 91/05795, 92/17505 and 95/17206, hereby incorporated by reference including drawings), osteoprotegerin (PCT Publication No. 97/23614, hereby incorporated by reference including drawings), novel erythropoiesis stimulating protein (NESP) (PCT Publication No. 94/09257, hereby incorporated by reference including drawings), leptin (OB protein) (see PCT publication Nos. 96/40912, 96/05309, 97/00128, 97/01010 and 97/06816 hereby

incorporated by reference including figures),
megakaryocyte growth differentiation factor (see, PCT
Publication No. 95/26746 hereby incorporated by
reference including figures), tumor necrosis factor-
5 binding protein (TNF-bp), interleukin-1 receptor
antagonist (IL-1ra), brain derived neurotrophic factor
(BDNF), glial derived neurotrophic factor (GDNF),
keratinocyte growth factor (KGF) and thrombopoietin.
The term proteins, as used herein, includes peptides,
10 polypeptides, consensus molecules, analogs, derivatives
or combinations thereof.

In general, EPO useful in the present
invention has the sequence of human erythropoietin, or
closely related analogues thereof. The EPO may be
15 produced by mammalian cells outside the body, or it may
be isolated from natural sources. Preferably, the EPO
is recombinant human EPO (rHuEPO) produced as described
in U. S. Patent No. 4,703,008 to Lin, the disclosure of
which is incorporated herein by reference. The amino
20 acid sequence of EPO is that depicted herein in SEQ ID
NO:1. The preferred host cells are Chinese Hamster
Ovary (CHO) cells as described in Example 10 of the Lin
patent. Other host cells known in the art, e.g. baby
hamster kidney cells, may also be used to produce EPO
25 useful in the present invention. While the procedures
of Example 10 in the Lin patent are the preferred
method for producing rEPO, modifications and changes
could be made to that process as known in the art. The
preferred concentration of EPO is 50 IU/mL - 500,000
30 IU/mL, and 750 IU/mL - 48,000 IU/mL is more preferred.

NESP of the present invention is a
hyperglycosylated EPO analog comprising two additional
glycosylation sites with an additional carbohydrate
chain attached to each site. NESP was constructed
35 using site-directed mutagenesis and expressed in

mammalian host cells. Details of the production of NESP are provided in co-owned PCT Application No. US94/02957. New N-linked glycosylation sites for rHuEPO were introduced by alterations in the DNA sequence to encode the amino acids Asn-X-Ser/Thr in the polypeptide chain. DNA encoding NESP was transfected into Chinese Hamster Ovary (CHO) host cells and the expressed polypeptide was analyzed for the presence of additional carbohydrate chains. In a preferred embodiment, NESP will have two additional N-linked carbohydrate chains at residues 30 and 88. The numbering of the amino acid sequence is that of human erythropoietin (EPO). The amino acid sequence of NESP is that depicted herein in SEQ ID NO:2. It is understood that NESP will have the normal complement of N-linked and O-linked glycosylation sites in addition to the new sites. The preferred concentration of NESP is 1 µg/mL - 5000 µg/mL, and 10 µg/mL - 500 µg/mL is more preferred.

The EPO and NESP of the present invention may also include conservative amino acid changes at one or more residues in SEQ ID NOs:1 and 2. These changes do not result in addition of a carbohydrate chain and will have little effect on the biological activity of the analog. These are set forth in Table 1, below. See generally, Creighton, *Proteins, passim* (W.H. Freeman and Company, N.Y., 1984); Ford et al., *Protein Expression and Purification* 2:95-107 (1991), which are herein incorporated by reference.

Table 1
Conservative Amino Acid Substitutions

Basic:	arginine
--------	----------

	lysine histidine
Acidic:	glutamic acid aspartic acid
Polar:	glutamine asparagine
Hydrophobic:	leucine isoleucine valine
Aromatic:	phenylalanine tryptophan tyrosine
Small:	glycine alanine serine threonine methionine

Therapeutic uses of the compositions of the present invention depend on the biologically active agent used. One skilled in the art will readily be able to adapt a desired biologically active agent to the present invention for its intended therapeutic uses. Therapeutic uses for such agents are set forth in greater detail in the following publications hereby incorporated by reference including drawings.

Therapeutic uses include but are not limited to uses for proteins like consensus interferon (see, U.S. Patent Nos. 5,372,808, 5,541,293, hereby incorporated by reference including drawings), interleukins (see, U.S. Patent No. 5,075,222, hereby incorporated by reference including drawings), erythropoietins (see, U.S. Patent Nos. 4,703,008, 5,441,868, 5,618,698, 5,547,933, 5,621,080, 5,756,349, and 5,955,422, hereby

incorporated by reference including drawings),
granulocyte-colony stimulating factors (see, U.S.
Patent Nos. 4,999,291, 5,581,476, 5,582,823, 4,810,643
and PCT Publication No. 94/17185, hereby incorporated
5 by reference including drawings), megakaryocyte growth
differentiation factor (see, PCT Publication No.
95/26746), stem cell factor (PCT Publication Nos.
91/05795, 92/17505 and 95/17206, hereby incorporated by
reference including drawings), OB protein (see
10 PCT publication Nos. 96/40912, 96/05309, 97/00128,
97/01010 and 97/06816 hereby incorporated by reference
including figures), and novel erythropoiesis
stimulating protein (PCT Publication No. 94/09257,
hereby incorporated by reference including drawings).
15 In addition, the present compositions may also be used
for manufacture of one or more medicaments for
treatment or amelioration of the conditions the
biologically active agent is intended to treat.

As relates specifically to NESP, the present
20 invention provides for a method of raising and
maintaining hematocrit in a mammal comprising
administering a therapeutically effective amount of
NESP in a pharmaceutical composition of the present
invention, wherein the NESP is administered less
25 frequently than an equivalent molar amount of rHuEPO to
obtain a comparable target hematocrit. The dosing
frequency of the present invention in order to reach a
patient's optimal hematocrit range is less than three
times per week. Dosing frequencies may be two times
30 per week, one time per week, or less than one time per
week, such as one time every other week, once per month
or once every two months. The dosing frequency
required to maintain a patient's target hematocrit is
less than three times per week. Dosing frequencies may
35 be two times per week, one time per week, or less than

one time per week, such as one time every two weeks, once per month or once every two months.

The invention may be employed with any condition resulting in a decrease in red blood cell levels, such as anemia associated with a decline or loss of kidney function, (chronic renal failure) myelosuppressive therapy, cancer, viral infection, chronic disease and excessive loss of blood during surgical procedures.

It is envisioned that the formulations of the present invention will additionally contain a buffering agent, e.g., alkali salts (sodium or potassium phosphate or their hydrogen or dihydrogen salts), sodium citrate/citric acid, sodium acetate/acetic acid, and any other pharmaceutically acceptable pH buffering agent known in the art, to maintain the pH of the solution within a desired range. Mixtures of these buffering agents may also be used. The amount of buffering agent useful in the composition depends largely on the particular buffer used and the pH of the solution. For example, acetate is a more efficient buffer at pH 5 than pH 6 so less acetate may be used in a solution at pH 5 than at pH 6. The preferred pH of the preferred formulations will be in the range of 5.0 to 7.0, and pH-adjusting agents such as hydrochloric acid, citric acid, sodium hydroxide, or a salt thereof, may also be included in order to obtain the desired pH.

The formulations will also contain sorbitan mono-9-octadecenoate poly(oxy-1,2-ethanediyl) derivatives, including but not limited to, polysorbate 80 or polysorbate 20. Other derivatives are well known in the art. The amount of polysorbate 20 or 80 to be used will be in the range of 0.001% to 0.1% (w/v). The preferred amount is 0.005% (w/v) in the single use and multi-dose formulations.

In order to provide EPO and/or NESP pharmaceutical formulations having superior stability, free L-methionine will be included in the formulations. The amount of free L-methionine included will be in the
5 range of 0.05mM to 50mM. In HSA-containing formulations, the preferred amount in the single use formulations is 0.05mM to 5mM, and the preferred amount in the multi-dose formulations is 1mM to 10mM. In HSA-free
10 use formulations, the preferred amount in the single amount in the multi-dose formulations is 1mM to 10mM.

Preservatives contemplated for use in the multi-dose formulations of the present invention include benzyl alcohol, benzalkonium chloride,
15 chlorobutanol, cresol, phenol, and parabens. The amount of preservative included will be in the range of 0% to 2% (w/v) and the preferred amount in the formulations is 1% (w/v).

The formulations of the present invention may
20 further include an isotonicity adjusting agent to render the solution isotonic and more compatible for injection. Typical tonicity agents are well known in the art and include but are not limited to sodium chloride, mannitol, glycine, and sorbitol. The
25 preferred agent is sodium chloride within a concentration range of 0mM to 200mM.

It is also envisioned that other anti-oxidants may be included in the formulations of the present invention. Anti-oxidants contemplated for use
30 in the preparation of the formulations include amino acids such as glycine and lysine, chelating agents such as EDTA and DTPA, and free-radical scavengers such as sorbitol and mannitol.

Preferred NESP formulations contemplated for
35 use in the present invention will contain 1-5000 µg/mL

NESP, 10mM to 30mM phosphate buffer, 100mM to 200mM NaCl, 0.001% to 0.1%(w/v) polysorbate 80, and 0.5mM to 50mM L-methionine, pH 5.0-7.0; and more preferably, 10-500 µg/mL NESP, 20mM phosphate buffer, 140mM NaCl, 5 0.005%(w/v) polysorbate 80, and 1mM L-methionine, pH 6.2.

Preferred EPO formulations contemplated for use in the present invention will contain 50-500,000 IU/mL EPO, 0.01mM to 5mM phosphate buffer, 0.01mM to 10 150mM NaCl, 5mM to 50mM L-arginine or L-histidine or salt thereof, 0.001% to 0.1% (w/v) polysorbate 80, and 0.5mM to 50mM L-methionine, pH 5.0-7.0; and more preferably, 750-48,000 IU/mL EPO, 2mM phosphate buffer, 110mM NaCl, 43.1mM L-arginine HCl, 0.006 % (w/v) 15 polysorbate 80, and 0.5, 1, 2, 3 or 5mM L-methionine, pH 6.0; or 2mM phosphate buffer, 142mM NaCl, 9.54mM L-histidine HCl, 0.006% (w/v) polysorbate 80, and 0.5, 1, 2, 3 or 5mM L-methionine, pH 6.0.

Also contemplated for use in inhibiting 20 oxidation of methionine is nitrogen overlay. Nitrogen overlay can be introduced to the headspace of a vial or prefilled syringe by purging nitrogen during the filling process.

25 The following examples are offered to more fully illustrate the invention, but are not to be construed as limiting the scope thereof.

Example 1

30

This example describes the preparation of EPO and NESP HSA containing and HSA-free single use and multi-dose formulations. The EPO and NESP protein

preparations were prepared as described in the Materials and Methods section below.

NESP and/or EPO HSA-containing formulations were then prepared by adding 0.1-1% albumin, the appropriate buffering agents (e.g., sodium phosphate), and a tonicity modifier (e.g., sodium chloride) to the protein preparation to obtain formulations having the desired concentrations of protein and excipients. NESP and/or EPO HSA-free formulations were prepared by replacing the albumin with other recombinant proteins or pharmaceutically acceptable surfactants (e.g. polysorbate 20 or 80). Multi-dose formulations were prepared by introducing preservative(s) (e.g. benzyl alcohol) to the HSA-containing or HSA-free formulations.

Example 2

This example describes experiments wherein the effect of free L-methionine on the aggregation (introduced by light) of NESP was evaluated. Although the underlying mechanism is not clear, under extreme conditions, light introduces significant aggregation to the NESP formulations. NESP single use, HSA-free formulations prepared as described in Example 1 were used in the experiment.

The glass vials containing the protein were placed into a UV light box and were incubated overnight (16 hours) with continuous UV light exposure. The samples were analyzed with SEC-HPLC. As depicted in Figure 1, addition of 10mM free methionine significantly decreased the rate of aggregation.

Example 3

This example describes experiments wherein
5 the effect of free L-methionine on the aggregation of
NESP in the presence of benzyl alcohol was evaluated.
Although the underlying mechanism is not clear, benzyl
alcohol introduces very minor aggregation to the NESP
formulations even during storage at 2-8°C. NESP multi-
10 dose, HSA-free formulations prepared as described in
Example 1 were used in the experiment.

Multi-dose formulations containing 1% benzyl
alcohol were incubated for 13 months at 2-8°C and
analyzed with SEC-HPLC method. As depicted in Figure
15 2, addition of 1mM-20mM free methionine significantly
decreased the rate of aggregation.

Example 4

20 This example describes experiments wherein
various additives and treatments were tested for their
ability to inhibit methionine oxidation in the NESP
HSA-free single use formulations. NESP HSA-free single
use formulations prepared as described in Example 1
25 were used in the experiments.

First, the protective effect of various anti-
oxidants on NESP was examined by hydrogen peroxide
spiking experiment (described in the Materials and
Methods section below). Free amino acids L-lysine,
30 glycine and L-methionine were tested and the %
oxidation was determined by tryptic mapping as
described in the Materials and Methods section below.
It was demonstrated convincingly that free L-methionine
prevents the oxidation of the Met-54 residue of NESP in
35 the presence of excess hydrogen peroxide (see Table 1).

Table 1

	<u>Anti-Oxidant</u>	<u>NESP Met-54 Oxidation (%)</u>
5	Glycine	100
	Lysine	100
	Methionine	37.3
	Glycine + Lysine	100
10	Glycine + Methionine	35.3
	Lysine + Glycine + Methionine	32.9

Next, the protective effect of various additives and treatments on NESP was examined. A NESP HSA-free formulation was used as a control. Additives tested were 20mM L-Methionine, 10mM histidine and 0.1mM EDTA. Nitrogen overlay in the head space was also evaluated. It was determined that free L-Methionine, EDTA, histidine, and/or nitrogen overlay can effectively inhibit the oxidation of Met-54 residue of NESP HSA-free formulations against various oxidative agents such as peroxide, superoxide ions (see Figure 3). The combination of free L-Methionine with either EDTA or histidine was more effective in inhibiting the oxidation than individual additives (see Figure 3). The combination of free L-Methionine and nitrogen overlay in the head space was also more effective in individual treatment (see Figure 3).

Example 5

This example describes experiments wherein various additives and treatments were tested for their ability to inhibit methionine oxidation in EPO and/or NESP HSA-free multi-dose formulations. EPO and/or NESP HSA-free multi-dose formulations prepared as described in Example 1 were used in the experiments.

First, the protective effect of various concentrations of free L-Methionine on NESP HSA-free multi-dose formulations was examined by hydrogen peroxide spiking experiments as described in Example 2.

5 The formulations contained 1% benzyl alcohol and free methionine concentrations ranging from 0-20mM were tested. Samples were incubated for 56 days at either 4°C or 29°C. The addition of free L-Methionine was found to be effective in inhibiting the oxidation

10 induced by benzyl alcohol impurity in the multi-dose formulation (see Figures 4 and 5).

Next, the effect of methionine on HSA-free EPO formulations \pm benzyl alcohol was evaluated. Figure 6 compares the tryptic maps of EPO in solutions

15 with and without benzyl alcohol, and it is clear that the addition of this particular lot of benzyl alcohol can lead to nearly complete oxidation of EPO in solution at pH 7.0. However, the addition of free L-Methionine can completely prevent the oxidation of EPO

20 in a solution containing the same benzyl alcohol.

In addition, it was determined that purging the buffer solution with nitrogen could also significantly reduce the rate of Met-54 oxidation of NESP by benzaldehyde (see Figure 7). This indicates

25 that free L-Methionine can inhibit the oxidative effect of dissolved molecular oxygen on Met-54 of NESP.

Example 6

30 This example describes experiments wherein the effect of methionine 54 oxidation on the biological activity of NESP was evaluated. First, NESP formulations were oxidized with 0.01% hydrogen peroxide for different duration such that NESP samples

35 containing different amounts of oxidized methionine 54

residue could be obtained. It was determined that the oxidation of methionine 54 does not adversely affect biological activity of NESP or EPO (see Table 2).

5

Table 2

	<u>Oxidation (%)</u>	<u>Activity (%)</u>	
		<u>In vitro</u>	<u>in vivo</u>
10	Control	121	121
	15	92	133
	39	95	125
	57	90	109
	76	102	100
15	100	95	106

Next, a sufficient concentration of hydrogen peroxide was added and the samples incubated for several days such that all the methionine 54 residue in the NESP solution are oxidized even in the presence of added free L-methionine. It was determined that under extreme oxidative stress, NESP loses biological activity, in that samples that did not contain free methionine lost significant biological activity (see Table 3).

Table 3

	<u>Sample</u>	<u>Methionine</u>	<u>Activity (%)</u>
		<u>Oxidation (%)</u>	
30	0mM Met, 0.25% H ₂ O ₂ , 6 days	100	37
	5mM Met, 0.25% H ₂ O ₂ , 6 days	100	85
35	10mM Met, 0.25% H ₂ O ₂ , 6 days	100	91
	20mM Met, 0.25% H ₂ O ₂ , 6 days	100	85
	40mM Met, 0.25% H ₂ O ₂ , 6 days	100	77

40 The inactivation of NESP was ascribed to the oxidation of other residues than methionine. Tryptophan, cysteine, and histidine were identified as additional oxidation sites (see Figure 8). Addition of free methionine prevents the oxidative inactivation of NESP

by protecting these critical amino acids from oxidation (Table 3).

Materials and Methods

5

The EPO used in the present invention may be prepared according to the above incorporated-by-reference U.S. Patent No. 4,703,008 (Lin).

10 The NESP used in the present invention may be prepared according to the above incorporated-by-reference PCT Publication No. 94/09257.

15 Tryptic mapping of NESP or EPO was carried out by digesting the proteins with commercially available trypsin followed by separation of peptides with reversed-phase HPLC. A typical experiment would be carried out as follows: an aliquot of 20 μ L trypsin digestion buffer, containing 20mM Methionine, 500mM Tris (Base), and 5M Urea at pH 8.2, will be added to 180 μ L of sample followed by the addition of 4 μ L of 1 mg/mL trypsin solution. After 18 hours of digestion at room temperature, the digested samples were analyzed by reversed-phase HPLC using a Phenomenex Jupiter C18 (250 x 4.6, 300 A) column.

25 Hydrogen peroxide spiking experiments were carried out by adding small aliquots of hydrogen peroxide to the sample to be tested. After incubation for a predetermined time at room temperature, the reaction was stopped by quenching free peroxide with the addition of 100mM excess free L-methionine.

30

The present invention has been described in terms of particular embodiments found or proposed to comprise preferred modes for the practice of the invention. It will be appreciated by those of ordinary skill in the art that, in light of the present

35

disclosure, numerous modifications and changes can be made in the particular embodiments exemplified without departing from the intended scope of the invention.

WHAT IS CLAIMED IS:

1. A pharmaceutical formulation comprising a biologically active agent and methionine, wherein
5 said formulation demonstrates improved stability, and wherein said formulation does not contain human serum albumin.
2. A formulation according to Claim 1
10 wherein said methionine is present in a concentration of about 0.5mM-50mM.
3. A formulation according to Claim 2 wherein said active agent is selected from the group
15 consisting of peptides, small molecules, carbohydrates, nucleic acids, lipids, proteins, and analogs thereof.
4. A formulation according to Claim 3 wherein said active ingredient is a protein.
20
5. A formulation according to Claim 4 wherein said protein is erythropoietin (EPO).
6. A formulation according to Claim 5
25 wherein said EPO has an amino acid sequence as depicted in SEQ ID NO:1.
7. A formulation according to Claim 6 further comprising a pH buffering agent which provides
30 a pH range of about 5 to about 7.
8. A formulation according to Claim 7 further comprising a stabilizing amount of a sorbitan mono-9-octadecenoate poly(oxy-1,2-ethanediyl)

derivative which is present in a concentration of about 0.001% to 0.1% (w/v).

9. A formulation according to Claim 4
5 wherein said protein is novel erythropoiesis stimulating protein (NESP) or a chemically modified form thereof.

10. A formulation according to Claim 9
10 wherein said NESP has an amino acid sequence as depicted in SEQ ID NO:2.

11. A formulation according to Claim 10
further comprising a pH buffering agent which provides
15 a pH range of about 5 to about 7.

12. A formulation according to Claim 11
further comprising a stabilizing amount of a sorbitan
mono-9-octadecenoate poly(oxy-1,2-ethanediyl)
20 derivative which is present in a concentration of about 0.001% to 0.1% (w/v).

13. A pharmaceutical multi-dose formulation
comprising a biologically active agent, a preservative,
25 and methionine, wherein said formulation demonstrates improved stability, and wherein said formulation does not contain human serum albumin.

14. A formulation according to Claim 13
30 wherein said methionine is present in a concentration of about 0.5mM to 50mM.

15. A formulation according to Claim 14
wherein said active agent is selected from the group

consisting of peptides, small molecules, carbohydrates, nucleic acids, lipids, proteins, and analogs thereof.

16. A formulation according to Claim 15
5 wherein said active ingredient is a protein.

17. A formulation according to Claim 16
wherein said protein is erythropoietin (EPO).

10 18. A formulation according to Claim 17
wherein said EPO has an amino acid sequence as depicted
in SEQ ID NO:1.

19. A formulation according to Claim 18
15 wherein said preservative is benzyl alcohol which is
present in a concentration of about 0% to 2% (w/v).

20. A formulation according to Claim 19
further comprising a pH buffering agent which provides
20 a pH range of about 5 to about 7.

21. A formulation according to Claim 20
further comprising a stabilizing amount of a sorbitan
mono-9-octadecenoate poly(oxy-1,2-ethanediyl)
25 derivative which is present in a concentration of about
0.001% to 0.1% (w/v).

22. A formulation according to Claim 16
wherein said protein is novel erythropoiesis
30 stimulating protein (NESP) or a chemically modified
form thereof.

23. A formulation according to Claim 22
wherein said NESP has an amino acid sequence as
35 depicted in SEQ ID NO:2.

24. A formulation according to Claim 23 wherein said preservative is benzyl alcohol which is present in a concentration of about 0% to 2% (w/v).

5

25. A formulation according to Claim 24 further comprising a pH buffering agent which provides a pH range of about 5 to about 7.

10

26. A formulation according to Claim 25 further comprising a stabilizing amount of a sorbitan mono-9-octadecenoate poly(oxy-1,2-ethanediyl) derivative which is present in a concentration of about 0.001% to 0.1% (w/v).

15

27. A method of stabilizing a pharmaceutical composition of a biologically active agent which comprises adding methionine to said composition in amount sufficient to inhibit oxidation of methionine residues in the amino acid sequence of said biologically active agents; wherein said formulation does not contain human serum albumin.

20


Figure 1

Figure 2





Figure 3


Figure 4


Figure 5

Figure 6




Figure 7





Figure 8

A803.ST25.txt
SEQUENCE LISTING

<110> Li, Tiansheng
Chang, Byeong
Sloey, Christopher

<120> L-METHIONINE AS A STABILIZER FOR NESP/EPO IN HSA-FREE FORMULATIONS

<130> A-803

<140> TBD

<141> 2001-08-30

<160> 2

<170> PatentIn version 3.0

<210> 1

<211> 165

<212> PRT

<213> Homo sapiens

<400> 1

```

Ala Pro Pro Arg Leu Ile Cys Asp Ser Arg Val Leu Glu Arg Tyr Leu
1           5           10
Leu Glu Ala Lys Glu Ala Glu Asn Ile Thr Thr Gly Cys Ala Glu His
20          25          30
Cys Ser Leu Asn Glu Asn Ile Thr Val Pro Asp Thr Lys Val Asn Phe
35          40          45
Tyr Ala Trp Lys Arg Met Glu Val Gly Gln Gln Ala Val Glu Val Trp
50          55          60
Gln Gly Leu Ala Leu Leu Ser Glu Ala Val Leu Arg Gly Gln Ala Leu
65          70          75
Leu Val Asn Ser Ser Gln Pro Trp Glu Pro Leu Gln Leu His Val Asp
85          90          95
Lys Ala Val Ser Gly Leu Arg Ser Leu Thr Thr Leu Leu Arg Ala Leu
100         105        110
Gly Ala Gln Lys Glu Ala Ile Ser Pro Pro Asp Ala Ala Ser Ala Ala

```

A803.ST25.txt

115	120	125
Pro Leu Arg Thr Ile Thr Ala Asp Thr Phe Arg Lys Leu Phe Arg Val		
130	135	140
Tyr Ser Asn Phe Leu Arg Gly Lys Leu Lys Leu Tyr Thr Gly Glu Ala		
145	150	155
Cys Arg Thr Gly Asp		
	165	

<210> 2

<211> 165

<212> PRT

<213> Homo sapiens

<400> 2

Ala Pro Pro Arg Leu Ile Cys Asp Ser Arg Val Leu Glu Arg Tyr Leu		
1	5	10
Leu Glu Ala Lys Glu Ala Glu Asn Ile Thr Thr Gly Cys Asn Glu Thr		
20	25	30
Cys Ser Leu Asn Glu Asn Ile Thr Val Pro Asp Thr Lys Val Asn Phe		
35	40	45
Tyr Ala Trp Lys Arg Met Glu Val Gly Gln Gln Ala Val Glu Val Trp		
50	55	60
Gln Gly Leu Ala Leu Leu Ser Glu Ala Val Leu Arg Gly Gln Ala Leu		
65	70	75
Leu Val Asn Ser Ser Gln Val Asn Glu Thr Leu Gln Leu His Val Asp		
85	90	95
Lys Ala Val Ser Gly Leu Arg Ser Leu Thr Thr Leu Leu Arg Ala Leu		
100	105	110
Gly Ala Gln Lys Glu Ala Ile Ser Pro Pro Asp Ala Ala Ser Ala Ala		
115	120	125
Pro Leu Arg Thr Ile Thr Ala Asp Thr Phe Arg Lys Leu Phe Arg Val		
130	135	140
Tyr Ser Asn Phe Leu Arg Gly Lys Leu Lys Leu Tyr Thr Gly Glu Ala		
145	150	155
Cys Arg Thr Gly Asp		
	165	

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US02/27855

A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) : A61K 38/00

US CL : 514/12, 970, 973; 930/90

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 514/12, 970, 973; 930/90

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

Please See Continuation Sheet

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X — Y	US 5,929,028 (SKRABANJA et al) 27 July 1999 (27.07.99), abstract, Table I, Col. 4, lines 64-66.	1-4, 13-16, and 27 ----- 1-27
X — Y	US 5,272,135 A (TAKURI) 21 December 1993 (21.12.93) abstract, Col. 1-2, Col. 6, line 1, Example III	1-4, 27 ----- 1-6, 9-10, 13-18, 22-23, 27
X, P — Y, P	US 2002/0037841 (PAPADIMITRIOU) 28 March 2002 (28.03.02) sections [0004]-[0008], [0011], [0021]-[0022], [0048], [0123], [0211].	1-8, 13-21, and 27 ----- 1-27
Y	US 4,835,260 (SHOEMAKER) 30 May 1989 (30.05.89) Col. 1-2; combine with teachings of 5,929,028 or 5,272,135.	1-27

☐ Further documents are listed in the continuation of Box C.

☐ See patent family annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T"

later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X"

document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y"

document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&"

document member of the same patent family

Date of the actual completion of the international search

13 November 2002 (13.11.2002)

Date of mailing of the international search report

04 FEB 2003

Name and mailing address of the ISA/US

Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703)305-3230

Authorized officer

Holly Schnizer

Telephone No. (703) 308-0196

KAREN COCHRANE CARLSON, PH.D
PRIMARY EXAMINER

INTERNATIONAL SEARCH REPORT

PCT/US02/27855

Continuation of B. FIELDS SEARCHED Item 3:

STN (Bioscience); EAST (all databases), sequence search, search terms: EPO, erythropoietin, oxidized, oxidation, methionine, met, stability

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.

This Page Blank (uspto)